The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Open accessAbstract
BACKGROUND: Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma. METHODS: We randomly assigned patients with supratentorial glioblastoma to receive intravenous bevacizumab (10 mg per kilogram of body weight every 2 weeks) or placebo, plus radiotherapy (2 Gy 5 days a week; maximum, 60 Gy) and oral temozolomide (75 mg per square meter of body-surface area per day) for 6 weeks. After a 28-day treatment break, maintenance bevacizumab (10 mg per kilogram intravenously every 2 weeks) or placebo, plus temozolomide (150 to 200 mg per square meter per day for 5 days), was continued for six 4-week cycles, followed by bevacizumab monotherapy (15 mg per kilogram intravenously every 3 weeks) or placebo until the disease progressed or unacceptable toxic effects developed. The coprimary end points were investigator-assessed progression-free survival and overall survival. RESULTS: A total of 458 patients were assigned to the bevacizumab group, and 463 patients to the placebo group. The median progression-free survival was longer in the bevacizumab group than in the placebo group (10.6 months vs. 6.2 months; stratified hazard ratio for progression or death, 0.64; 95% confidence interval [CI], 0.55 to 0.74; P<0.001). The benefit with respect to progression-free survival was observed across subgroups. Overall survival did not differ significantly between groups (stratified hazard ratio for death, 0.88; 95% CI, 0.76 to 1.02; P=0.10). The respective overall survival rates with bevacizumab and placebo were 72.4% and 66.3% at 1 year (P=0.049) and 33.9% and 30.1% at 2 years (P=0.24). Baseline health-related quality of life and performance status were maintained longer in the bevacizumab group, and the glucocorticoid requirement was lower. More patients in the bevacizumab group than in the placebo group had grade 3 or higher adverse events (66.8% vs. 51.3%) and grade 3 or higher adverse events often associated with bevacizumab (32.5% vs. 15.8%). CONCLUSIONS: The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma. Improved progression-free survival and maintenance of baseline quality of life and performance status were observed with bevacizumab; however, the rate of adverse events was higher with bevacizumab than with placebo. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT00943826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationAaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Research works printed but not linked: 4
- 10.1215/15228517-5-2-89 · doi:10.1215/15228517-5-2-89
- 10.2307/2336502 · DOI · Paper page
- Henriksson R, Bottomley A, Mason W, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Presented at the 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, May 31–June 4, 2013. · doi:10.1200/jco.2013.31.15_suppl.2005
- Armstrong TS, Won M, Wefel JS, et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Presented at the 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, May 31–June 4, 2013. · doi:10.1200/jco.2013.31.15_suppl.2003
Cited by
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationEnhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,862
Artificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationGarcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Self-citationWeller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationStupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Self-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Self-citationChallenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
Alexander, B. M., & Cloughesy, T. F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0119 · Cited by 788
Self-citationHigh-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 772
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Weller, M., van den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E., Frappaz, D., Henriksson, R., Balana, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 750
Self-citationAlbert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Genetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Molecular targeted therapy of glioblastoma
Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 585
Self-citationMGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
Self-citationCurrent and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 577
Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R.-D., Krex, D., Grauer, O., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 568
Self-citationLiau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1507-6 · Cited by 537
Self-citationEmerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Self-citation(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 472
Kickingereder, P., Isensee, F., Tursunova, I., Petersen, J., Neuberger, U., Bonekamp, D., Brugnara, G., Schell, M., Kessler, T., Foltyn, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30098-1 · Cited by 454
Self-citationPredictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
Henrik Heiland, D., Ravi, V. M., Behringer, S. P., Frenking, J. H., Wurm, J., Joseph, K., Garrelfs, N. W. C., Strähle, J., Heynckes, S., Grauvogel, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10493-6 · Cited by 437
Clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.050 · Cited by 431
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Ahir, B. K., Engelhard, H. H., & Lakka, S. S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01892-8 · Cited by 424
Primary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 419
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 405
Glioblastoma Stem Cells: Driving Resilience through Chaos
Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G., & Rich, J. N. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.009 · Cited by 401
Lombardi, G., De Salvo, G. L., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397
Self-citationProspects of immune checkpoint modulators in the treatment of glioblastoma
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.139 · Cited by 388
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Filley, A. C., Henriquez, M., & Dey, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21586 · Cited by 386
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 350
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Klughammer, J., Kiesel, B., Roetzer, T., Fortelny, N., Nemc, A., Nenning, K.-H., Furtner, J., Sheffield, N. C., Datlinger, P., Peter, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0156-x · Cited by 332
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 324
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Self-citationPeterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Temozolomide for immunomodulation in the treatment of glioblastoma
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy072 · Cited by 300
Nonsurgical Treatment of Recurrent Glioblastoma
Gallego, O. (2015) · Current Oncology · doi:10.3747/co.22.2436 · Cited by 296
Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone
Lemée, J.-M., Clavreul, A., & Menei, P. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov119 · Cited by 295
Sandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 293
Self-citationHombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
Epithelial-mesenchymal transition in glioblastoma progression
IWADATE, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4113 · Cited by 288
Glioma: experimental models and reality
Lenting, K., Verhaak, R., ter Laan, M., Wesseling, P., & Leenders, W. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1671-4 · Cited by 287
Glioblastoma stem‐like cells secrete the pro‐angiogenic VEGF‐A factor in extracellular vesicles
Treps, L., Perret, R., Edmond, S., Ricard, D., & Gavard, J. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1359479 · Cited by 277
Itakura, H., Achrol, A. S., Mitchell, L. A., Loya, J. J., Liu, T., Westbroek, E. M., Feroze, A. H., Rodriguez, S., Echegaray, S., Azad, T. D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7582 · Cited by 272
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
Kickingereder, P., Götz, M., Muschelli, J., Wick, A., Neuberger, U., Shinohara, R. T., Sill, M., Nowosielski, M., Schlemmer, H.-P., Radbruch, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0702 · Cited by 267
Self-citationNayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., Nghiemphu, L., Kaley, T., Colman, H., McCluskey, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2500 · Cited by 265
Immune Evasion Strategies of Glioblastoma
Razavi, S.-M., Lee, K. E., Jin, B. E., Aujla, P. S., Gholamin, S., & Li, G. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00011 · Cited by 262
Griveau, A., Seano, G., Shelton, S. J., Kupp, R., Jahangiri, A., Obernier, K., Krishnan, S., Lindberg, O. R., Yuen, T. J., Tien, A.-C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.020 · Cited by 261
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Chukwueke, U. N., & Wen, P. Y. (2019) · CNS Oncology · doi:10.2217/cns-2018-0007 · Cited by 256
Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M. C., Herrlinger, U., Ketter, R., Schlegel, U., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 254
Self-citationGarcía-Romero, N., Carrión-Navarro, J., Esteban-Rubio, S., Lázaro-Ibáñez, E., Peris-Celda, M., Alonso, M. M., Guzmán-De-Villoria, J., Fernández-Carballal, C., de Mendivil, A. O., García-Duque, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13635 · Cited by 230
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
“Thus far, with the exception of the BELOB phase II study,theresultsofanti-VEGF/anti-VEGFRtrialshavebeenmodest,with improvements inradiographicresponses, tumor-associatedbrainedema, and PFS without an increase in OS.163 Decreased perfusion after excessive tumor vessel pruning could block the clearance of chemotherapuet…”
BackgroundMethodInfluentialMa, W., Wang, Y., Zhang, R., Yang, F., Zhang, D., Huang, M., Zhang, L., Dorsey, J. F., Binder, Z. A., O’Rourke, D. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00147-8 · Cited by 143
Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors
Iv, M., Telischak, N., Feng, D., Holdsworth, S. J., Yeom, K. W., & Daldrup-Link, H. E. (2015) · Nanomedicine · doi:10.2217/nnm.14.203 · Cited by 134
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0582 · Cited by 119
Self-citationHabashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Tamura, R., Tanaka, T., Ohara, K., Miyake, K., Morimoto, Y., Yamamoto, Y., Kanai, R., Akasaki, Y., Murayama, Y., Tamiya, T., et al. (2019) · Cancer Science · doi:10.1111/cas.13889 · Cited by 75
Huang, J., Campian, J. L., Gujar, A. D., Tsien, C., Ansstas, G., Tran, D. D., DeWees, T. A., Lockhart, A. C., & Kim, A. H. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2775-y · Cited by 52
Reardon, D. A., Lassman, A. B., Schiff, D., Yunus, S. A., Gerstner, E. R., Cloughesy, T. F., Lee, E. Q., Gaffey, S. C., Barrs, J., Bruno, J., et al. (2018) · Cancer · doi:10.1002/cncr.31172 · Cited by 50
Self-citationMDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
Boxerman, J. L., Zhang, Z., Safriel, Y., Rogg, J. M., Wolf, R. L., Mohan, S., Marques, H., Sorensen, A. G., Gilbert, M. R., & Barboriak, D. P. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy049 · Cited by 35
Zhang, C., Yang, X., Fu, C., & Liu, X. (2018) · Gene · doi:10.1016/j.gene.2018.06.030 · Cited by 30
Metadata
- Authors
- Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., Brandes, A. A., Hilton, M., Abrey, L., & Cloughesy, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-20
- Volume
- 370
- Issue
- 8
- Pages
- 709-722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2156330848
- Cited by
- 2,557
- References
- 35
- FWCI
- 130.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.